SEC Form 4 · accession 0001731122-19-000008
Enochian Biosciences Inc · ENOB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Dybul
Officer — Executive Vice Chair · Director
Period of report
Dec 31, 2018
Accepted (ET)
Jan 3, 2019 · 9:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001527728
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 31, 2018 | J | 3,732 | $0.00 | A | 55,336 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 31, 2018, Mark Dybul received 3,732 shares of common stock pursuant to a contractual right to receive shares upon the exercise of warrants by RS Bio ApS.